CAR-T therapies: a breakdown of key developments for mesothelioma, lymphoma and solid tumors

From next-generation therapies for mesothelioma to dual-targeting approaches for lymphoma, CAR-T therapy is expanding treatment options for aggressive cancers. CAR-T therapy has made significant strides, moving beyond its initial success in blood cancers to show promise in treating solid tumors. In this listicle, we explore advancements in this field, highlighting novel strategies that address key challenges. We delve into mesothelin-targeted therapies for mesothelioma, review key approvals for lymphomas as well as innovative approaches for solid tumors, including targeted protein degradation and the use of 'on/off' switches to combat T-cell exhaustion. Mesothelioma The standard of care for mesothelioma has historically been...